Physician profile
Michael Husak
NPI 1386679959
$764.65
in general payments reported to CMS, 2019-2025
14 companies · $53.45 in 2025
The $53.45 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $340 · 2022: $121 · 2023: $95.95 · 2024: $154 · 2025: $53.45.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $250 · Education: $53.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $249.76 |
| Education | $53.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $227.86 | 2019-2025 | Tecentriq, Phesgo |
| Gilead Sciences, INC. | $139.05 | 2023-2024 | Trodelvy |
| Janssen Biotech, INC. | $125.78 | 2019-2024 | Erleada, Akeega |
| Merck Sharp & Dohme LLC | $44.00 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $39.84 | 2019-2022 | |
| Amgen INC. | $39.77 | 2019 | |
| Novartis Pharmaceuticals Corporation | $27.93 | 2019 | |
| Janssen Pharmaceuticals, INC | $21.18 | 2019 | |
| Astellas Pharma US INC | $20.20 | 2022 | |
| Puma Biotechnology, INC. | $19.45 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $19.41 | 2019 | |
| Genzyme Corporation | $16.43 | 2019 | |
| Pharmaessentia USA Corporation | $12.25 | 2022 | |
| Taiho Oncology, INC. | $11.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Husak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.